Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Cash from Financing Activities (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of Cash from Financing Activities data on record, last reported at -$5.0 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 112.5% year-over-year to -$5.0 million; the TTM value through Dec 2025 reached -$30.0 million, up 70.59%, while the annual FY2025 figure was -$30.0 million, 70.59% up from the prior year.
  • Cash from Financing Activities reached -$5.0 million in Q4 2025 per INDV's latest filing, down from -$3.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $40.0 million in Q4 2024 and bottomed at -$56.0 million in Q1 2024.